Dissecting Tumor Intrinsic and Immune Drivers of Resistance to Therapy in Non-Small Cell Lung Cancer


Damon Runyon - Mark Foundation Physician-Scientist (2020-Present)

The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the development of immune-activating checkpoint inhibitors, given alone or with chemotherapy. However, most patients’ tumors eventually develop resistance to these drugs. Dr. Vokes is investigating this process by collecting data on the genetic and immune features of pre- and post-treatment tumors. She will then use computational algorithms to integrate these features into a model that predicts which patients are likely to respond to checkpoint inhibitor therapy and also sheds light on the difference between therapy given alone or with chemotherapy. A better understanding of how tumors evolve resistance will guide the design of more effective therapies for all patients and improve therapy selection for individuals.

Content courtesy of Damon Runyon Cancer Research Foundation

BACK TO OUR PORTFOLIO